Companion Diagnostics Market
Companion Diagnostics Market - Global Industry Assessment & Forecast
#
Pages:
149
2022
Feb - 2023
VMR-2021
Segments Covered
By
Product & Service Assays, Kits & Reagents, Software & Services
-
By
Technology Next-Generation Sequencing, In Situ Hybridization, Immunohistochemistry, Other Technologies
-
By
Indication Cancer, Neurological Disorders, Cardiovascular Disorders, Infectious Diseases, Other Indication
-
By
End Users Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, Contract Research Organizations, Other End Users
-
By
Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
 Base Year:
|
2022 |
| Forecast
Years:
|
2023 - 2030 |
 Historical
Years:
|
2017 - 2021 |
 Revenue
2022: |
USD 5.59 Billion |
 Revenue 2030:
|
USD 13.74 Billion |
 Revenue CAGR
(2023 - 2030): |
11.90% |
Fastest Growing Region (2023 -
2030)
|
Asia Pacific |
Largest Region (2022):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
| Sr. No. | Offering | Report Coverage |
| 1. | Market Size | In terms of Revenue (USD Million) |
| 2. | Historic Data | 2017 to 2021 |
| 3. | Forecast Data | 2023 to 2030 |
| 4. | Market Drivers, Restraints, Opportunities, & Regional Market Trends | Yes |
| 5. | Market Attractiveness Analysis | Yes |
| 6. | Segment Analysis | Maximum Segments |
| 7. | Regional Coverage | 5 Regions |
| 8. | Country Coverage | Top 22 Countries |
| 9. | Competitive Landscape and Company Market Share Analysis | Yes. Exhaustive information will be provided in two separate chapters of Competitive Landscape and Company Profiles. |
| 10. | Porter’s Five Forces Analysis | Yes. |
| 11. | Value Chain Analysis | Yes |
| 12. | PEST Analysis | Yes |
| 13. | Regulatory Landscape | Yes |
| 14. | Technology Landscape | Yes |
| 15. | COVID-19 Impact Analysis | Yes. Exhaustive information for Key Strategies Undertaken by Companies, Impact Assessment of the COVID-19 Pandemic by Region, along with Short-term and Long-term dynamics. |
| 16. | Top startups to watch out for | Yes |
| 17. | Top 3 Trends to Watch | Yes |
| 18. | Top 3 Strategies Followed by Major Players | Yes |
| 19. | Top 3 Predictions by Vantage Market Research | Yes |
| 20. | Discussion Guide | Yes |
| 21. | Key Primary Respondents - VERBATIM | Yes |
| 22. | Transcripts from the Primary Respondents | Additional Cost USD 1,000 |
| 23. | Others/Miscellaneous | |
Vantage Market
Research | 28-Feb-2023
FAQ
Frequently Asked Question
What is the global demand for Companion Diagnostics in terms of revenue?
-
The global Companion Diagnostics valued at USD 5.59 Billion in 2022 and is expected to reach USD 13.74 Billion in 2030 growing at a CAGR of 11.90%.
Which are the prominent players in the market?
-
The prominent players in the market are Abbott Laboratories Molecular Inc. (U.S.), Agilent (Dako Denmark A/S) (U.S.), ARUP Laboratories Inc. (U.S.), BioMerieux (France), Danaher Corporation (Leica Microsystems) (Germany), Foundation Medicine Inc. (U.S.), Myriad Genetics Inc. (U.S.), Roche (Ventana Medical Systems Inc.) (U.S.), Thermo Fisher Scientific (Life Technologies Corporation) (Germany), QIAGEN N.V. (Germany).
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 11.90% between 2023 and 2030.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Companion Diagnostics include
- Increased popularity of personalized medicine
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Companion Diagnostics in 2022.
